Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 824 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Terminated Phase 2 Interventional Results available

Ibrutinib and Rituxan for Chronic GVHD

NCT04235036
Conditions
Graft Vs Host Disease
Interventions
Rituximab, Ibrutinib
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Stroke
Interventions
Tele-AutoCITE, CI therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Low Back Pain, Chronic
Interventions
45-Degree Roman Chair Exercise
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Graft Versus Host Disease
Interventions
Photopheresis, Methylprednisolone
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia
Interventions
Oblimersen-rituximab-fludarabine
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Buffalo, New York • New Hyde Park, New York
Conditions
Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease
Interventions
Neihulizumab (ALTB-168)
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 10 more
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Conditions
Left-Hemisphere Stroke
Interventions
Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Diagnostic Test
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Conditions
Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
Interventions
Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Other
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
2,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Conditions
Kidney Diseases, Chronic Kidney Diseases
Interventions
Community health worker intervention, Standard Care (in control arm)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Denver, Colorado • Albuquerque, New Mexico
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Conditions
Graft-versus-host Disease
Interventions
Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg, Neihulizumab
Biological · Drug
Lead sponsor
Sameem M. Abedin, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Chronic Graft Versus Host Disease
Interventions
Ofatumumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Tampa, Florida • Minneapolis, Minnesota + 1 more
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Conditions
AML
Interventions
Mycophenolate Mofetil, Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Graft Versus Host Disease
Interventions
Axatilimab, Biospecimen Collection, Questionnaire Administration, Skin Biopsy, Skin Measurement
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Seattle, Washington
Conditions
Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

NCT06874283
Conditions
Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
Interventions
Eye exam
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Graft-Versus-Host Disease(GVHD)
Interventions
5-Azacytidine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

IVIG-eye Drops Treatment for Dry Eye Disease

NCT03992482
Conditions
Dry Eye
Interventions
Intravenous Immune Globulin (IVIG), Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bone Marrow Transplant Complications, Graft-versus-Host Disease
Interventions
HORIZONS Intervention, Minimally enhanced usual care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Conditions
Chronic Low Back Pain
Interventions
Biomodulator, Usual Care (Medication + Exercise)
Device · Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 62 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas